clinical trialsbriefings.

Glowing digital data particles representing AI-driven drug discovery converge on a stone archway symbolizing regulatory evidence requirements.

AI Discovers Drugs. It Doesn't Approve Them.

AI drug discovery has drawn billions in investment but zero FDA approvals, and the bottleneck sponsors need to plan for is evidence, not speed.

Glowing molecular structures hover above empty hospital gurneys in a dim laboratory, symbolizing the gap between AI-driven discovery and clinical trial execution.

The AI Drug Discovery Boom Is Outrunning Trial Execution

Generative AI is accelerating molecule design, but no AI-discovered drug has cleared trials, and regulators have yet to define how AI governs the trials themselves.

Rows of archived clinical trial samples in cold storage, with one vial illuminated as if being re-examined by new analysis.

The Next Regulatory Question Isn't the Model. It's the Data It Rescued.

AI-driven reanalysis of failed clinical trials is producing new evidence outside the systems built to validate it, and GxP quality frameworks have not caught up.

A researcher examines a molecular model in a lab with abstract data visualizations glowing in the background.

FDA's Other AI Track: Drug Development Gets Its Own Playbook

While FDA's device guidance draws attention, a parallel track for AI in early-phase clinical trials and drug development is quietly taking shape.